HAN Lin-hong, ZHAO Yu-han, WANG Xiao-ying, ZHU Yan. Targeting platelet-immune cell interaction as a new strategy for post-myocardial infarction current evidence and future prospectiveJ. Acta Pharmaceutica Sinica, 2024, 59(6): 1519-1526. DOI: 10.16438/j.0513-4870.2023-0124
Citation: HAN Lin-hong, ZHAO Yu-han, WANG Xiao-ying, ZHU Yan. Targeting platelet-immune cell interaction as a new strategy for post-myocardial infarction current evidence and future prospectiveJ. Acta Pharmaceutica Sinica, 2024, 59(6): 1519-1526. DOI: 10.16438/j.0513-4870.2023-0124

Targeting platelet-immune cell interaction as a new strategy for post-myocardial infarction current evidence and future prospective

  • Myocardial infarction (MI) is a fatal disease with high morbidity and mortality. Platelets are major players of thrombosis and inflammation after acute myocardial infarction. There is growing evidence that platelets mediate inflammation, participate in dead tissue removal and heart remodeling through direct or indirect interactions with immune cells post-MI. This paper reviews the type of interactions between platelets and immune cells after myocardial infarction, and summarizes the mechanism of platelet interaction with different immune cells, such as neutrophils, monocytes, and macrophages, to mediate cardiac injury and repair through up-regulation of surface receptors and release of immune regulatory mediators post-MI. Therapeutic strategies targeting the interaction between platelets and immune cells for myocardial infarction is also presented, to provide reference for the exploration of new immune therapy targets for myocardial infarction.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return